Cambridge, Mass., June 25, 2019 – Generation Bio, a company developing the first genetic medicines that can be re-dosed and titrated to effect for a lifetime, today announced the appointment of Katherine Fitzgerald, Ph.D., an international leader in the field of innate immunity, to its Scientific Advisory Board.
“Kate has dedicated her career to understanding the molecular basis of the inflammatory process that underlies a range of serious diseases,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. “We are pleased to welcome her to our Scientific Advisory Board and look forward to leveraging her insights on innate immunity and disease pathogenesis as we advance our diverse portfolio of therapeutic candidates.”
Dr. Fitzgerald is a professor of medicine and director of the Program in Innate Immunity within the Division of Infectious Disease and Immunology at the University of Massachusetts Medical School, where she has worked since 2001. At the University, she serves as principal investigator of the Fitzgerald Lab, working with post-doctoral fellows and graduate students to understand how dysregulation of innate immunity plays a central role in the pathogenesis of infectious, inflammatory and autoimmune disease. Dr. Fitzgerald has received numerous awards for her research and has been named a Thomson Reuters Highly Cited Researcher multiple times, recognizing her as being among the most frequently cited researchers in the field of immunology. Kate received her Bachelor of Science in biochemistry from the University of Cork, Ireland and her doctorate in biochemistry from Trinity College Dublin, Ireland.
“Generation Bio’s ceDNA technology has the potential to enable durable treatment of genetic diseases driven by chronic inflammation across a variety of tissue types,” said Dr. Fitzgerald. “I look forward to contributing my insights to the Scientific Advisory Board and supporting the company’s efforts to change the lives of patients on a global scale.”
About Generation Bio
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people to live unaffected by inherited disease. The company is using its proprietary ceDNA platform to create gene therapies with drug-like properties – delivering durable gene expression with the ability to re-dose for individual patient titration and for the potential to sustain effect over a lifetime. Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.generationbio.com or follow @generationbio.
Ten Bridge Communications